15,826 Shares of Jazz Pharmaceuticals PLC $JAZZ Purchased by Pegasus Asset Management Inc.

Key Points

• Pegasus Asset Management initiated a position of 15,826 Jazz Pharmaceuticals shares in Q3, valued at approximately $3.66 million. Institutional investors collectively own 89.14% of the company.
• Jazz reported quarterly revenue of $1.24 billion, beating expectations of $1.21 billion and rising 10.4% year over year; the company also raised its 2026 revenue outlook. Analysts’ consensus rating is “Moderate Buy,” with an average price target of $293.45.
• Company insiders sold 102,534 shares worth about $25.2 million over the past three months. CEO Renée Galá and CAO Patricia Carr made disclosed sales and retained 140,394 and 6,512 shares, respectively.

Pegasus Asset Management Inc. bought a new position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 15,826 shares of the specialty pharmaceutical company's stock, valued at approximately $3,664,000.

A number of other large investors have also recently bought and sold shares of the company. AlphaCentric Advisors LLC lifted its stake in Jazz Pharmaceuticals by 29.8% during the 3rd quarter. AlphaCentric Advisors LLC now owns 4,688 shares of the specialty pharmaceutical company's stock valued at $1,085,000 after acquiring an additional 1,075 shares during the period. International Assets Investment Management LLC acquired a new stake in shares of Jazz Pharmaceuticals in the third quarter worth $225,000. Calamos Advisors LLC increased its stake in shares of Jazz Pharmaceuticals by 764.2% in the third quarter. Calamos Advisors LLC now owns 12,366 shares of the specialty pharmaceutical company's stock worth $2,863,000 after acquiring an additional 10,935 shares during the period. Inscription Capital LLC increased its stake in shares of Jazz Pharmaceuticals by 67.9% in the third quarter. Inscription Capital LLC now owns 1,990 shares of the specialty pharmaceutical company's stock worth $461,000 after acquiring an additional 805 shares during the period. Finally, TFB Advisors LLC purchased a new position in shares of Jazz Pharmaceuticals during the third quarter worth $410,000. Hedge funds and other institutional investors own 89.14% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on JAZZ shares. Barclays upped their price target on shares of Jazz Pharmaceuticals from $271.00 to $275.00 and gave the company an "overweight" rating in a report on Tuesday, November 3rd. Wells Fargo & Company increased their price target on Jazz Pharmaceuticals from $285.00 to $300.00 and gave the stock an "overweight" rating in a research report on Tuesday, August 4th. Morgan Stanley lifted their price objective on Jazz Pharmaceuticals from $314.00 to $319.00 and gave the company an "overweight" rating in a research note on Tuesday, November 3rd. Robert W. Baird boosted their price objective on Jazz Pharmaceuticals from $252.00 to $280.00 and gave the company an "outperform" rating in a report on Tuesday, August 4th. Finally, Weiss Ratings downgraded Jazz Pharmaceuticals from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Wednesday, October 28th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $293.45.

Insider Activity

In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 1,413 shares of Jazz Pharmaceuticals stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $231.36, for a total transaction of $326,911.68. Following the sale, the chief accounting officer owned 6,512 shares of the company's stock, valued at $1,506,616.32. The trade was a 17.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Renee D. Gala sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction on Tuesday, November 3rd. The stock was sold at an average price of $225.37, for a total transaction of $225,370.00. Following the sale, the chief executive officer directly owned 140,394 shares in the company, valued at approximately $31,640,595.78. This trade represents a 0.71% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 102,534 shares of company stock valued at $25,185,243 in the last three months. Company insiders own 4.10% of the company's stock.

Key Jazz Pharmaceuticals News

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz beat quarterly estimates, reporting $1.24 billion in revenue versus roughly $1.21 billion expected, with revenue up 10.4% year over year. Coverage also reported that the company raised its 2026 revenue outlook to approximately $4.78 billion–$4.85 billion, helping reinforce the growth outlook. Q3 results and outlook
• Positive Sentiment: RBC, Barclays, Morgan Stanley and JPMorgan issued favorable commentary or raised price targets after the results. The analyst optimism adds support to the stock’s post-earnings momentum. Barclays price-target update
• Neutral Sentiment: CEO Renée Galá sold 1,000 shares under a pre-arranged Rule 10b5-1 plan and retained 140,394 shares. Director Bruce Cozadd also sold 6,000 shares under a pre-arranged plan, while CAO Patricia Carr sold 1,413 shares and retained 6,512. These sales may draw investor attention, but planned transactions are not necessarily a signal about near-term business prospects. Insider transaction coverage

Jazz Pharmaceuticals Trading Up 3.3%

JAZZ stock opened at $234.76 on Friday. The company has a current ratio of 1.82, a quick ratio of 1.58 and a debt-to-equity ratio of 1.09. Jazz Pharmaceuticals PLC has a 12-month low of $128.80 and a 12-month high of $266.38. The stock has a market cap of $15.07 billion, a price-to-earnings ratio of 79.85, a PEG ratio of 0.44 and a beta of 0.38. The business's 50-day moving average is $229.39 and its 200 day moving average is $217.74.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) EPS for the quarter, beating analysts' consensus estimates of ($4.03) by $0.15. The business had revenue of $1.24 billion during the quarter, compared to analysts' expectations of $1.21 billion. Jazz Pharmaceuticals had a return on equity of 16.88% and a net margin of 4.37%. The business's revenue was up 10.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $8.13 earnings per share. On average, sell-side analysts anticipate that Jazz Pharmaceuticals PLC will post 11.08 EPS for the current fiscal year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious diseases, particularly in neuroscience and oncology. Founded in 2003, the company is headquartered in Dublin, Ireland, and serves patients in the United States and international markets.

Its products include treatments for sleep disorders and seizure conditions, such as Xywav, Xyrem, Sunosi and Epidiolex. Jazz also offers medicines used in cancer care, including Zepzelca, Vyxeos and Rylaze, as well as Defitelio for a serious complication following stem cell transplantation.

Jazz expanded its portfolio through acquisitions, including the 2021 acquisition of GW Pharmaceuticals, which added Epidiolex and other cannabinoid-based medicines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.